RCS - Immune Pharmaceuticl - Immune Pharmaceuticals Proposal to Exit Bankruptcy
Immune Pharmaceuticals, Inc. (IMNPQ) Proposal to Exit Bankruptcy.
Immune Pharmaceuticals Inc. is in early-stage discussions with United General LTD, a UK Institutional Investment firm.
Immune Pharmaceuticals Inc.'s trustee and representatives are exploring options to restructure the company with United General LTD.
Adeel Ahmed, CFO and Managing partner of United General LTD, is leading the current discussions with Immune Pharmaceuticals Inc.
According to United General an initial interest has been presented for acquiring Immune Pharmaceuticals, Inc.
According to the preliminary conversations between legal representatives, both sides have agreed to explore all legal avenues to achieve exiting bankruptcy.
Further details surrounding a potential reorganization plan may be announced once a legal pathway can be agreed.
There can be no assurance that any definitive proposal will be made, or accepted by the bankruptcy court or Immune Pharmaceuticals, Inc., and that any agreement can be executed or that any transactions with the trustee or legal council will be approved or consummated.
The company's debt holders and large shareholders are encouraged to contact Adeel Ahmed of United General LTD directly for additional information and syndication opportunities in relation to Immune Pharmaceuticals, Inc.
Adeel can be contacted at; a.ahmed@unitedgeneral.co.uk
(www.unitedgeneral.co.uk)
This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDNRAJPMTTMTIBBFB
